Χώρα: Ισραήλ
Γλώσσα: Αγγλικά
Πηγή: Ministry of Health
OXANTEL AS EMBONATE; PRAZIQUANTEL; PYRANTEL EMBONATE
ELIEZER LINEVITZ LTD.
TABLETS
OXANTEL AS EMBONATE 500.7 MG; PYRANTEL EMBONATE 124.85 MG; PRAZIQUANTEL 125 MG
PER OS
Required
VETOQUINOL S.A., FRANCE
For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages of nematodes and cestode species : Nemtodes : toxocara canis toxocaris leonine ancylostoma caninum uncinaria stenocephala trichuris vulpis. Cestodes : Dipylidum caninum taenia spp.
2020-08-31
VETERINARY MEDICINE PACKAGE LEAFLET This medicine is dispensed with a veterinarian’s prescription only For use in animals only DOLPAC 10 VETERINARY - oral tablets for dogs DOLPAC 25 VETERINARY - oral tablets for dogs COMPOSITION: ACTIVE INGREDIENTS: DOLPAC 10 VETERINARY: DOLPAC 25 VETERINARY: 200.28 mg of oxantel (as embonate) 49.94 mg of pyrantel (as embonate) 50.00 mg of praziquantel 500.70 mg of oxantel (as embonate) 124.85 mg of pyrantel (as embonate) 125.00 mg of praziquantel INACTIVE INGREDIENTS: dextrates, povidone K30, lauryl sodium sulphate, bacon flavor, crospovidone, sodium stearyl fumarate. INDICATION: Treatment of parasitic infestation with adult stages of roundworms and tapeworms in dogs NEMATODES AND CESTODES: NEMATODES: Toxocara canis, Toxascaris leonina, Ancylostoma caninum, Uncinaria stenocephala, Trichuris vulpis. CESTODES: Dipylidium caninum, Taenia spp_._ SIDE EFFECTS: Vomiting and diarrhea may appear in the dog during the course of treatment. Anorexia is a common side effect of praziquantel; however, it was not observed in studies of Dolpac. If you notice any serious side effect not mentioned in this leaflet, tell your veterinarian. You can report side effects to the Ministry of Health by following the link ‘Reporting Side Effects of Drug Treatment’ on the Ministry of Health home page (www.health.gov.il) which links to an online form for reporting side effects. You can also use this link: https://sideeffects.health.gov.il DOSAGE AND DIRECTIONS FOR USE: Dosage table: DOLPAC 10 The recommended dose is 20 mg oxantel / 5 mg pyrantel / 5 mg praziquantel per kg bodyweight, which is one tablet DOG WEIGHT NUMBER OF TABLETS 3.1-5 kg 5.1-10 kg 10.1-20 kg 20.1-30 kg ½ 1 2 3 per 10 kg bodyweight. For oral administration. DOLPAC 25 The recommended dose is 20 mg oxantel / 5 mg pyrantel / 5 mg praziquantel per kg bodyweight, which is one tablet per 25 kg bodyweight. For oral administration. DOG WEIGHT NUMBER OF TABLETS 10.1-12.5 kg 12.6-25 kg 25.1-50 kg 50.1-75 kg ½ 1 2 3 Administer the required nu Διαβάστε το πλήρες έγγραφο
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DOLPAC 10 VETERINARY DOLPAC 25 VETERINARY 2. QUALITATIVE AND QUANTITATIVE COMPOSITION DOLPAC 10 VETERINARY: Oxantel …………………………………………………...(as embonate) (equivalent to 559 mg of oxantel embonate) 200.28 mg Pyrantel…………………………………………………...(as embonate) (equivalent to 144 mg of oxantel embonate) 49.94 mg Praziquantel …………………………………………….. 50.00 mg Excipient QS for one pre-scored 950-mg tablet For the full list of excipients, see ‘List of excipients’ section. DOLPAC 25 VETERINARY: Oxantel …………………………………………………...(as embonate) (equivalent to 1395,5 mg of oxantel embonate) 500.70 mg Pyrantel…………………………………………………...(as embonate) (equivalent to 360 mg of oxantel embonate) 124.85 mg Praziquantel …………………………………………….. 125.00 mg Excipient QS for one pre-scored 2375-mg tablet For the full list of excipients, see ‘List of excipients’ section. 3. PHARMACEUTICAL FORM Tablet. Pale yellow to yellow oblong tablet with breaking line. 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs. 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For curative treatment of dogs harbouring mixed parasitic infestations with the following adult stages of nematodes and cestode species : Nemtodes : toxocara canis, toxocaris leonine, ancylostoma caninum, uncinaria stenocephala, trichuris vulpis. Cestodes : Dipylidum caninum taenia spp. 4.3. CONTRAINDICATIONS See ‘Interaction with other medicinal products and other forms of interactions’ section. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 4.4. SPECIAL WARNINGS FOR EACH TARGET SPECIES Parasite resistance to any particular class of anthelmintic may develop following frequent and repeated use of an anthelmintic from that class. As fleas serve as intermediate Διαβάστε το πλήρες έγγραφο